Azithromycin Dosing and Administration Guidelines

Standard Adult Dosing Regimens

The American College of Cardiology recommends a standard Z-pack regimen of 500 mg on day 1, followed by 250 mg once daily on days 2 through 5, for a total 5-day course, for respiratory tract infections including community-acquired pneumonia, acute bacterial sinusitis, and bronchitis 1, 2
A 3-day regimen of 500 mg once daily for 3 consecutive days is equally effective for respiratory tract infections and provides the same total 1.5 gram dose 2
A single-dose regimen of 1 gram is recommended for non-gonococcal urethritis, cervicitis, and Chlamydia trachomatis infections 1, 2

The standard pediatric regimen for respiratory tract infections is 10 mg/kg (maximum 500 mg) on day 1, followed by 5 mg/kg once daily (maximum 250 mg/day) on days 2-5 1, 2
For pertussis in infants <6 months, the recommended dose is 10 mg/kg per day for 5 days 1
For pertussis in children ≥6 months, the recommended dose is 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg (max 250 mg) on days 2-5 1

The guideline society recommends separating azithromycin from aluminum- or magnesium-containing antacids by at least 2 hours, as antacids reduce absorption by up to 50% 2
Obtain baseline ECG in patients with cardiac risk factors before initiating therapy, and avoid azithromycin if QTc >450 ms (men) or >470 ms (women) 3, 4

Dispense medication on-site and directly observe the first dose when possible to maximize adherence, particularly in sexually transmitted infection treatment 1
Azithromycin is NOT first-line for streptococcal pharyngitis due to increasing macrolide resistance in group A Streptococcus, and should only be used as an alternative in penicillin-allergic patients for strep throat 3
Do not use azithromycin as monotherapy for gonococcal infections due to resistance; must combine with ceftriaxone 2

Azithromycin is considered safe in pregnancy and is classified as Pregnancy Category B, preferred over erythromycin in infants <1 month due to lower risk of infantile hypertrophic pyloric stenosis 1

Community‑acquired pneumonia and acute bacterial exacerbations of chronic bronchitis – In adults, a 5‑day regimen of 500 mg on day 1 followed by 250 mg once daily on days 2‑5 provides effective treatment. 7
Pediatric pneumonia caused by Mycoplasma pneumoniae or Chlamydophila pneumoniae – In children, a 5‑day course of 10 mg/kg on day 1 then 5 mg/kg once daily on days 2‑5 is recommended. 8
Bronchiolitis Obliterans Syndrome (lung‑transplant recipients) – An initial 5‑day loading dose of 250 mg daily, followed by 250 mg three times weekly for at least 3 months constitutes an adequate therapeutic trial. 9

Uncomplicated chlamydial urethritis and cervicitis – A single 1‑gram oral dose of azithromycin is sufficient for cure, achieving tissue concentrations above the MIC for ~10 days. (CDC/MMWR guidance) 10
Non‑gonococcal urethritis of unknown etiology – Recommended regimen: 500 mg on day 1 then 250 mg daily for 4 additional days (total 5 days). (European Urology) 11
Suspected or confirmed Mycoplasma genitalium – Same 5‑day regimen (500 mg day 1, then 250 mg daily for 4 days). (European Urology) 11
Documented macrolide‑resistant M. genitalium – Switch to moxifloxacin 400 mg daily for 7‑14 days rather than extending azithromycin therapy. (European Urology) 11
Lymphogranuloma venereum (LGV) – Some specialists advise 1 g azithromycin orally once weekly for 3 weeks, although supporting clinical data are limited. (MMWR) 12

Bronchiectasis with ≥3 exacerbations per year – Long‑term azithromycin should be continued for a minimum of 6 months. (Thorax) 13
Evidence‑based dosing for bronchiectasis – Effective regimens include 500 mg three times weekly, 250 mg daily, or an initial 250 mg three times weekly with titration based on response. (Thorax) 13
Sustained benefit after stopping therapy – Exacerbation reduction persists for 6 months after a 6‑month course is discontinued; the effect of restarting therapy is unknown. (Thorax) 13
Quality‑of‑life improvement – Continued azithromycin therapy for up to 1 year may be needed to achieve measurable quality‑of‑life gains. (Thorax) 13

Avoid extending azithromycin beyond evidence‑based durations – Unnecessary prolongation increases antimicrobial resistance without proven clinical benefit. (Clinical Infectious Diseases) 7
Extending therapy for persistent urethritis symptoms without objective signs – No demonstrated benefit; such extension should be avoided. (MMWR) 14
Uncertainty in long‑term continuation for BOS – It remains unclear whether azithromycin should be maintained beyond the initial 3‑month trial if a favorable response is observed. (European Respiratory Journal) 9